The global hypoparathyroidism treatment market was valued at US$ 777.4 million as of 2022 and is likely to reach US$ 841.9 million in 2023. During the 2023 to 2033 forecast period, the market is expected to incline at a CAGR of 7.7%, and is expected to total US$ 1,767.4 million by the end of the said period of assessment.
Parathyroid hormone (PTH) plays a pivotal role in maintaining the optimum level of calcium, phosphate, and calcitriol (active Vitamin D) in the blood and bones. Hypoparathyroidism is an uncommon endocrine disorder that develops due to low production or absence of parathyroid hormone.
Globally, hypoparathyroidism affects approximately 200, 000 people, out of which most cases are associated with accidental damage or removal of the parathyroid gland during thyroid surgery. Other cases are associated with autoimmune, hereditary, and idiopathic issues. The current standard treatment involves the use of calcium and vitamin D analogues (Vitamin D2 & Vitamin D3).
On the other hand, hormonal therapy is also gaining attention, where the primary treatment has found success in cases of severe hypoparathyroidism. The side effects include potential risks associated with developing osteosarcoma has limited adoption rates. Manufacturers in the market are focusing on investing significantly in the development of safe, and effective hormonal therapies in long-term strategies.
| Attributes | Details |
|---|---|
| Hypoparathyroidism Treatment Market Value (2022) | US$ 777.4 million |
| Hypoparathyroidism Treatment Market Value (2023) | US$ 841.9 million |
| Hypoparathyroidism Treatment Market Expected Value (2033) | US$ 1,767.4 million |
| Hypoparathyroidism Treatment Market Projected CAGR (2023 to 2033) | 7.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Between 2018 and 2022, the demand for calcium supplements for treating hypoparathyroidism dominated the global market mainly owing to cost and efficacy benefits over hormonal therapies and other drugs. Subsequently, rising research and development activities supported market growth.
NATPARA (Takeda), and Rocaltrol (Roche) are some of the commonly prescribed drugs to treat moderate to severe hypoparathyroidism. Issues of product recall and the resultant mismanagement of treatments have led to hospitalizations in severe cases. Manufacturers such as Ascendis Pharma A/S, EnteraBio Ltd, ProLynx, Inc., and Extend Biosciences, Inc. have hormonal therapies in the pipeline which have delivered superior patient outcomes.
The market is expected to witness an increase in patient screening for several thyroid conditions owing to growing patient awareness. The approval and designation of hypothyroidism drugs as orphan products by the United States FDA and the European Commission (EC), coupled with the untapped patient population is expected to have a positive impetus on market growth.
The emergence of personalized medicines, the rapid rise in demand for biologics for hypothyroidism, and consolidation activities by market players will create significant opportunities for the expansion of the hypothyroidism treatment market size over the forecast period, which is projected to expand at a CAGR of 7.7% through 2033.
Government Initiatives to Propel Market Growth
Government support in terms of receiving an orphan drug designation from regulatory bodies such as the United States FDA and European Commission (EC) and financial and tax incentive factors are expected to result in a high return on investment for companies developing novel drugs for treating hypoparathyroidism.
The United States FDA’s orphan drug status is given to biologics affecting fewer than 200,000 people in the United States alone with the benefits of various incentives including tax incentives for qualified clinical trials and market exclusiveness on receiving regulatory approval.
For hypoparathyroidism, NATPARA is the only drug issued with a black box warning, which was notified by United States FDA, in January 2015, and currently has exclusivity until 2022. Also, the treatment is covered by several insurance companies and co-pay policies. Such initiatives are expected to boost the production of novel drugs, which is expected to positively influence the growth of the market shortly.
Principal Consultant
Side Effects Owing to the Usage of NATPARA to Restrict the Market Expansion
Currently, NATPARA is the only available drug to treat hypoparathyroidism. Because of its side effects including a potential risk of osteosarcoma, high blood calcium levels, and reduced sense of touch or pain sensation in joints, which could result in hospitalization. The drug is only made available through NAPTARA Risk Evaluation and Mitigation Strategy (REMS) Programs.
Hence, in most of the cases, oral medications are considered as standard treatment for hypoparathyroidism. This limits the adoption of available hormonal therapy. Further, long-term beneficial drug usage symptoms have still not been demonstrated across clinical trials, which might limit the adoption of therapy in patients given the high price of the injection. Drug literature review 2018 states that therapy with rhPTH (1-84) is a long-term management option, where more long-term efficacy and safety data are needed in humans. EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for NATPARA instead of these side effects. Thus, labeling restrictions are expected to hold back the penetration of NATPARA in the major global markets, thereby hampering the overall growth of the market.
The Development of Biologics is Anticipated to Drive Market Growth
The hypoparathyroidism treatment market is shifting towards the demand for biologics over conventional drug alternatives. The efficacy of biologics and their ability to mimic natural body hormones is greater as compared to small molecule options in conventional therapy. This benefit is an essential influencing factor driving the demand for biologics.
Bologics promote the conversion of vitamin D into active forms, which increases the absorption of oral calcium supplements, resulting in synergies with conventional calcium in supplement therapy. Considering the aforementioned factors, the emergence of biologics is expected to offer lucrative opportunities for the growth of the hypothyroidism treatment market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
United States to Take Over the North American Market
NATPARA (parathyroid hormone), is a recombinant hormonal therapy approved in the United States for the treatment of hypoparathyroidism. It is prescribed to patients who do not show positive results from standard therapies including calcium supplements and vitamin D.
In September 2019, Takeda Pharmaceutical Company Limited announced the recall for all its doses of NATPARA injections in the United States This recall was attributed to the presence of small rubber particles in solution samples, which originated from the rubber septum of the NATPARA cartridge.
This recall of injectable PTH in the United States has created distress among the patients and had a significant impact on treatment cycles. Around 2,700 patients have been affected by the shortage. Patients who are currently being treated with the therapy, have been pushed back to oral medications including calcium supplements and activated vitamin D to control their symptoms.
This transition has created a negative impact on disease management, leading some patients to hospitalization because of severe hypocalcemia. Further, manufacturers anticipate that the PTH injectable will require another year to return to the market. United State has emerged as a leading market, held over 37.7% of the total demand registered in 2022.
High Incidence of Parathyroid Diseases in Germany to Propel The Market Growth
Factors such as rising occurrences of parathyroid diseases, rising government initiatives, increasing medical care expenditure, better regulatory scenarios, and rising reimbursement policies and funding are persistently aiding the expansion of the hypoparathyroidism treatment market in Germany. As indicated by the information proposed by Eurostat, it is seen that among the EU Member States, the largest share of medical care expenditure was recorded in Germany in 2019.
Further, growing approvals and orphan drug designation from the European Commission (EC), increasing candidates in clinical trials for the development of hormonal therapy, presence of pharmaceutical players, which leads to better availability of products across the continent, are some of the factors that are responsible for making Germany, one of the largest market for hypoparathyroidism in Europe. Germany held a market share of 8.2% in 2022.
Adoption of Sophisticated Technology to Raise The Market Demand in India
Implementation of government programs aimed at offering affordable and quality healthcare is expected to complement the growth of India's biopharma industry, in turn creating opportunities for the hypoparathyroidism treatment market. Increasing adoption of technologically advanced treatment and rising awareness among people in India is fuelling the demand for hypoparathyroidism treatment.
India is also considered one of the top destinations of thyroid related disorders in the world, increasing the need for the Hypoparathyroidism Treatment market in the region. Increasing patient pool due to the rise in population, emergence of new diseases, and lifestyle changes are also boosting demand for biopharmaceuticals, which is expected to provide a high opportunity for providers of hypoparathyroidism treatment. The market in the India is poised to grow at a CAGR of 8.6% over the upcoming decades.
Calcium Supplements Segment to Grow Owing to The Lowered Side Effects
Hypoparathyroidism is characterized by low parathyroid hormone secretions which results in low calcium levels in the body. Calcium supplements are preferred as the first line of treatment by doctors to normalize the deficiency.
These supplements show a reduced risk of side effects as compared to hormonal therapy. The recent United States recall of the NATPARA compelled patients to opt for oral medication such as calcium supplements to treat the symptoms. These factors will drive demand for calcium supplements, accounting for the largest share of the global market. The calcium supplements segment accounted for a market revenue of 38.29% in 2022.
Oral Segment to Dominate the Industry
The oral segment by route of administration, held the highest market share due to rising product launches and the presence of a solid pipeline. Various factors like a rapid delivery of drugs, high efficacy, and a higher rate of bioavailability are projected to impel the oral segment development. For drugs having medium to high oral availability, the oral route of administration is effective.
Oral treatments limit the utilization of central lines for intravenous drug administration and accordingly, decrease the danger of complications related to it and also a hospital stay. The advancement of promising new medications and potential clinical pipeline applicants are a portion of the major factors expected to boost segment development. The oral segment held a market revenue of 66.67% in 2022.
Hospital Segment is to Expand Owing to The Rapid Delivery of Medications
The hospital and retail sales are expected to show the maximum share in the market among all distribution channels due to the increasing number of facilities and easy accessibility to patients. Also, the quick delivery of medicines is one of the major factors driving the market growth during the forecast period.
As there are rising numbers of cases of hypoparathyroidism, there is increasing demand for faster accessibility and availability of medicine to treat the disorder as rapidly as possible. Thus, hospitals and retail providers can provide medicines to patients at a faster rate which in turn increases the hypoparathyroidism treatment market.
The global hypoparathyroidism treatment market is dominated by top manufacturers -Takeda Pharmaceutical Company Limited., Entera Bio Ltd., F. Hoffmann-La Roche Ltd, Amgen Inc., and Ascendis Pharma A/S Manufacturers are focusing on enhancing their global and regional presence through acquisitions and collaboration strategies.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Hypoparathyroidism Treatment Market Value (2023) | US$ 841.9 million |
| Hypoparathyroidism Treatment Market Expected Value (2033) | US$ 1,767.4 million |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Segments Covered | Product Type, Route of Administration, Distribution Channel, Region |
| Key Companies Profiled | Takeda Pharmaceutical Company Limited.; Entera Bio Ltd.; Amgen Inc.; Ascendis Pharma A/S; F. Hoffmann-La Roche Ltd; ProLynx, Inc.; Extend Biosciences, Inc.; BionPharma Inc.; Teva Pharmaceuticals Ltd. |
| Customization & Pricing | Available upon Request |
The global hypoparathyroidism treatment market is estimated to be valued at US$ 841.9 million in 2023.
The global market for hypoparathyroidism treatment rose at a CAGR of 5.1% from 2017 to 2022
The global hypoparathyroidism treatment market is expected to progress at a CAGR of 7.7% from 2023 to 2033
The market in India is projected to rise at a CAGR of 8.6% over the upcoming decade
The global hypoparathyroidism treatment market is predicted to account for US$ 1,767.4 million by 2033.
United States has emerged as a leading market, holding over 37.7% of the total demand registered in 2022.
The market in China is projected to rise at a CAGR of 7.9% over the upcoming decade
The calcium supplements segment accounted for a market revenue of 38.29% in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Parathyroid Hormone
5.3.1.1. Natpara
5.3.1.2. Others
5.3.2. Vitamin D Analogue
5.3.2.1. Vitamin D2
5.3.2.2. Vitamin D3
5.3.3. Calcium Supplements
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Parenteral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Sales
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Product Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Product Type
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product Type
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Product Type
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Product Type
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product Type
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Product Type
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Product Type
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Product Type
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Product Type
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Product Type
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Product Type
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Product Type
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Product Type
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Product Type
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Product Type
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Product Type
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Product Type
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Product Type
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Product Type
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Product Type
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Product Type
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Product Type
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Product Type
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Product Type
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Product Type
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Product Type
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Product Type
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Takeda Pharmaceutical Company Limited.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Entera Bio Ltd.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Amgen Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Ascendis Pharma A/S
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. F. Hoffmann-La Roche Ltd
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. ProLynx, Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Extend Biosciences, Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. BionPharma Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Sun Pharmaceutical Industries Ltd.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Teva Pharmaceuticals Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Hypoparathyroidism Treatment Market
